SETD1B

Histone-lysine N-methyltransferase SETD1B

95 patent compounds predicted against SETD1B, 77 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21533614	1.00	1/20
SCHEMBL21533556	0.82	1/20
SCHEMBL21533446	0.80	1/20
SCHEMBL21533448	0.80	1/20
SCHEMBL21533449	0.77	1/20
SCHEMBL21533454	0.73	1/20
SCHEMBL21533505	0.72	1/20
SCHEMBL21533534	0.69	1/20
SCHEMBL21533555	0.68	1/20
SCHEMBL21533594	0.67	1/20
SCHEMBL21533445	0.65	1/20
SCHEMBL21533447	0.65	1/20
SCHEMBL21533615	0.64	1/20
SCHEMBL21533616	0.63	1/20
SCHEMBL21533585	0.62	1/20
SCHEMBL21533451	0.62	1/20
SCHEMBL21533444	0.62	1/20
SCHEMBL21533501	0.61	1/20
SCHEMBL21533612	0.60	1/20
SCHEMBL21533453	0.59	1/20

Germline variants in SETD1B on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full SETD1B gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to SETD1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer	PHASE2	COMPLETED
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)	PHASE1/PHASE2	NOT_YET_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
The Efficacy of Allo-HSCT in ND HR-CBF-AML	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)	nan	NO_LONGER_AVAILABLE
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors	nan	RECRUITING
SRSF2 Gene Mutation in Patients With t-MDS/AML	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SETD1B binder may also engage these)

Protein	Name	Similarity
Q8CFT2	—	1.000	Q8CFT2 →
Q66J90	—	1.000	Q66J90 →
SETD1A	Histone-lysine N-methyltransferase SETD1A	0.997	landscape →
Q6PEI3	—	0.996	Q6PEI3 →
Q80TZ9	—	0.996	Q80TZ9 →
PRRC2A	Protein PRRC2A	0.996	landscape →
Q5TM26	—	0.996	Q5TM26 →
Q9R0I7	—	0.995	Q9R0I7 →
P0CB49	—	0.995	P0CB49 →
Q62901	—	0.994	Q62901 →
Q62255	—	0.994	Q62255 →
Q1LY77	—	0.994	Q1LY77 →
TET3	Methylcytosine dioxygenase TET3	0.994	landscape →
O95886	—	0.994	O95886 →
Q5TZ18	—	0.994	Q5TZ18 →
A2D4R4	—	0.994	A2D4R4 →
Q08D57	—	0.994	Q08D57 →
P97838	—	0.994	P97838 →
P21999	—	0.994	P21999 →
P70459	—	0.994	P70459 →
F1QIC4	—	0.994	F1QIC4 →
P14653	—	0.994	P14653 →
Q6PFD5	—	0.994	Q6PFD5 →
Q86V15	—	0.994	Q86V15 →
Q9CWL2	—	0.993	Q9CWL2 →
Q04888	—	0.993	Q04888 →
E9PYH6	—	0.993	E9PYH6 →
B1AZP2	—	0.993	B1AZP2 →
O55170	—	0.993	O55170 →
A2T6H5	—	0.993	A2T6H5 →